Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0007623111 | Thyroid | PTC | circadian rhythm | 96/5968 | 210/18723 | 1.74e-05 | 1.82e-04 | 96 |
GO:0048026110 | Thyroid | PTC | positive regulation of mRNA splicing, via spliceosome | 16/5968 | 22/18723 | 9.98e-05 | 8.15e-04 | 16 |
GO:1902369110 | Thyroid | PTC | negative regulation of RNA catabolic process | 38/5968 | 75/18723 | 5.41e-04 | 3.47e-03 | 38 |
GO:004348916 | Thyroid | PTC | RNA stabilization | 30/5968 | 65/18723 | 1.11e-02 | 4.42e-02 | 30 |
GO:000838034 | Thyroid | ATC | RNA splicing | 270/6293 | 434/18723 | 7.50e-35 | 1.19e-31 | 270 |
GO:000037534 | Thyroid | ATC | RNA splicing, via transesterification reactions | 200/6293 | 324/18723 | 1.75e-25 | 7.39e-23 | 200 |
GO:000037734 | Thyroid | ATC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 197/6293 | 320/18723 | 6.54e-25 | 2.18e-22 | 197 |
GO:000039834 | Thyroid | ATC | mRNA splicing, via spliceosome | 197/6293 | 320/18723 | 6.54e-25 | 2.18e-22 | 197 |
GO:190331134 | Thyroid | ATC | regulation of mRNA metabolic process | 181/6293 | 288/18723 | 1.75e-24 | 5.54e-22 | 181 |
GO:005068434 | Thyroid | ATC | regulation of mRNA processing | 97/6293 | 137/18723 | 5.28e-19 | 7.25e-17 | 97 |
GO:000640127 | Thyroid | ATC | RNA catabolic process | 165/6293 | 278/18723 | 8.45e-19 | 1.14e-16 | 165 |
GO:004348435 | Thyroid | ATC | regulation of RNA splicing | 100/6293 | 148/18723 | 2.75e-17 | 2.72e-15 | 100 |
GO:000640227 | Thyroid | ATC | mRNA catabolic process | 140/6293 | 232/18723 | 5.08e-17 | 4.65e-15 | 140 |
GO:003465525 | Thyroid | ATC | nucleobase-containing compound catabolic process | 217/6293 | 407/18723 | 1.20e-16 | 1.04e-14 | 217 |
GO:000095624 | Thyroid | ATC | nuclear-transcribed mRNA catabolic process | 78/6293 | 112/18723 | 6.44e-15 | 4.07e-13 | 78 |
GO:004670024 | Thyroid | ATC | heterocycle catabolic process | 228/6293 | 445/18723 | 7.26e-15 | 4.50e-13 | 228 |
GO:004427025 | Thyroid | ATC | cellular nitrogen compound catabolic process | 229/6293 | 451/18723 | 2.25e-14 | 1.27e-12 | 229 |
GO:004802434 | Thyroid | ATC | regulation of mRNA splicing, via spliceosome | 70/6293 | 101/18723 | 2.29e-13 | 1.09e-11 | 70 |
GO:001943924 | Thyroid | ATC | aromatic compound catabolic process | 232/6293 | 467/18723 | 3.05e-13 | 1.44e-11 | 232 |
GO:190136124 | Thyroid | ATC | organic cyclic compound catabolic process | 238/6293 | 495/18723 | 1.12e-11 | 4.12e-10 | 238 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa04919 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa049191 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa049192 | Colorectum | SER | Thyroid hormone signaling pathway | 40/1580 | 121/8465 | 1.02e-04 | 1.06e-03 | 7.67e-04 | 40 |
hsa049193 | Colorectum | SER | Thyroid hormone signaling pathway | 40/1580 | 121/8465 | 1.02e-04 | 1.06e-03 | 7.67e-04 | 40 |
hsa049194 | Colorectum | MSS | Thyroid hormone signaling pathway | 46/1875 | 121/8465 | 5.04e-05 | 4.97e-04 | 3.05e-04 | 46 |
hsa049195 | Colorectum | MSS | Thyroid hormone signaling pathway | 46/1875 | 121/8465 | 5.04e-05 | 4.97e-04 | 3.05e-04 | 46 |
hsa0491928 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa04919113 | Esophagus | ESCC | Thyroid hormone signaling pathway | 78/4205 | 121/8465 | 6.79e-04 | 2.23e-03 | 1.14e-03 | 78 |
hsa0491912 | Liver | HCC | Thyroid hormone signaling pathway | 75/4020 | 121/8465 | 8.76e-04 | 3.38e-03 | 1.88e-03 | 75 |
hsa0491913 | Liver | HCC | Thyroid hormone signaling pathway | 75/4020 | 121/8465 | 8.76e-04 | 3.38e-03 | 1.88e-03 | 75 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
THRA | CD8TEXINT | Colorectum | ADJ | SEMA3C,AGPAT4,NCEH1, etc. | 1.08e-01 | |
THRA | INCAF | Colorectum | CRC | RABL2B,NDUFAF6,PIGN, etc. | 4.72e-01 | |
THRA | ICAF | Colorectum | MSS | RABL2B,NDUFAF6,PIGN, etc. | 5.18e-01 | |
THRA | M1MAC | Endometrium | Healthy | USF1,ZNF483,AL356234.2, etc. | 4.31e-01 | |
THRA | SMC | Endometrium | ADJ | GUCY1A3,BRSK2,AC097724.3, etc. | 2.73e-01 | |
THRA | SMC | Endometrium | AEH | GUCY1A3,BRSK2,AC097724.3, etc. | 1.94e-01 | |
THRA | PERI | Liver | Cirrhotic | BAMBI,C2orf40,C15orf39, etc. | 1.40e-01 | |
THRA | SMC | Liver | Cirrhotic | BAMBI,C2orf40,C15orf39, etc. | 1.58e-01 | |
THRA | SMC | Liver | HCC | BAMBI,C2orf40,C15orf39, etc. | 3.49e-01 | |
THRA | CD8TEREX | Lung | MIAC | PLPP3,ZNF683,TRAF3IP2-AS1, etc. | 4.57e-02 | |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
THRA | SNV | Missense_Mutation | novel | c.1007N>G | p.Asp336Gly | p.D336G | P10827 | protein_coding | tolerated(0.13) | benign(0.133) | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
THRA | SNV | Missense_Mutation | novel | c.612N>T | p.Met204Ile | p.M204I | P10827 | protein_coding | tolerated(0.23) | benign(0.155) | TCGA-AC-A6IW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
THRA | SNV | Missense_Mutation | | c.32N>T | p.Gly11Val | p.G11V | P10827 | protein_coding | deleterious_low_confidence(0.01) | benign(0.08) | TCGA-E2-A14V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
THRA | insertion | In_Frame_Ins | novel | c.878_879insAAGGTCTGGCTGCTCTAAGAAATCAGC | p.Gly293_Val294insArgSerGlyCysSerLysLysSerAla | p.G293_V294insRSGCSKKSA | P10827 | protein_coding | | | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
THRA | SNV | Missense_Mutation | | c.1175N>T | p.Ser392Leu | p.S392L | P10827 | protein_coding | deleterious_low_confidence(0) | benign(0.039) | TCGA-EK-A2H0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
THRA | SNV | Missense_Mutation | | c.1175N>T | p.Ser392Leu | p.S392L | P10827 | protein_coding | deleterious_low_confidence(0) | benign(0.039) | TCGA-ZJ-A8QQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
THRA | SNV | Missense_Mutation | | c.871G>A | p.Gly291Ser | p.G291S | P10827 | protein_coding | deleterious(0.04) | probably_damaging(0.964) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
THRA | SNV | Missense_Mutation | | c.854A>G | p.Glu285Gly | p.E285G | P10827 | protein_coding | tolerated(0.23) | benign(0.012) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
THRA | SNV | Missense_Mutation | | c.473N>A | p.Pro158Gln | p.P158Q | P10827 | protein_coding | deleterious(0.02) | benign(0.077) | TCGA-DM-A1DA-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
THRA | SNV | Missense_Mutation | | c.709N>T | p.Pro237Ser | p.P237S | P10827 | protein_coding | deleterious(0.01) | possibly_damaging(0.85) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7067 | THRA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | | LEVOTHYROXINE | LEVOTHYROXINE | |
7067 | THRA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | agonist | 135651405 | TIRATRICOL | |
7067 | THRA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | agonist | 135651574 | LEVOTHYROXINE SODIUM | |
7067 | THRA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | | Dextrothyroxine Sodium | | |
7067 | THRA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | agonist | 178103533 | DEXTROTHYROXINE | |
7067 | THRA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | agonist | 135651573 | LIOTHYRONINE SODIUM | |
7067 | THRA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | agonist | CHEMBL1544 | LIOTHYRONINE | |
7067 | THRA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | | tiratricol | TIRATRICOL | |
7067 | THRA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | | TRIIODOTHYRONINE (T3) | | |
7067 | THRA | DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | antagonist | 135650713 | | |